{
  "id": "breast-cancer-cdk46-by-site",
  "display_name": "ER+/HER2- MBC (By Site)",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, All Patients, by Site, Q1 2023",
  "insight_type": "Treatment Patterns by Site",
  "summary": "CDK4/6 inhibitor utilization varies significantly by site, with Site A achieving 85% adherence to NCCN guidelines while Site C is at only 60%.",
  "recommendation": "Standardize CDK4/6 inhibitor utilization across all sites by implementing best practices from Site A.",
  "financial_impact": {
    "annual_opportunity": "$175,000/year",
    "math": "Improving CDK4/6 inhibitor utilization at lower-performing sites could generate approximately $175,000 in annual savings through improved progression-free survival."
  },
  "financial_impact_description": "Improving CDK4/6 inhibitor utilization at lower-performing sites could generate approximately $175,000 in annual savings through improved progression-free survival.",
  "peer_financial_impact": 220000,
  "peer_financial_impact_description": "Compared to peer organizations, there is a $220,000 annual opportunity by bringing all sites to benchmark performance.",
  "action_steps": [
    {
      "text": "Share best practices from Site A with other sites",
      "icon": "chart-bar"
    },
    {
      "text": "Develop standardized protocols for CDK4/6 inhibitor use",
      "icon": "user-group"
    },
    {
      "text": "Implement site-specific improvement plans for Sites C and D",
      "icon": "star"
    }
  ],
  "peer_action_steps": [
    "Benchmark each site against peer organizations",
    "Develop targeted improvement plans for underperforming sites",
    "Monitor progress monthly"
  ],
  "chart_data": {
    "categories": [
      "Site A",
      "Site B",
      "Site C",
      "Site D",
      "Site E"
    ],
    "values": [
      85,
      75,
      60,
      65,
      70
    ],
    "peer_values": [
      80,
      78,
      75,
      73,
      72
    ],
    "target_values": [
      85,
      85,
      85,
      85,
      85
    ]
  },
  "drilldowns": [],
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      {
        "name": "Site A",
        "value": 85,
        "gap": 0,
        "highlight": true
      },
      {
        "name": "Site B",
        "value": 75,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Site C",
        "value": 60,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Site D",
        "value": 65,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Site E",
        "value": 70,
        "gap": 0,
        "highlight": false
      }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "clinical_impact": {
    "description": "Clinical impact analysis based on outcomes data and peer-reviewed literature.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Potential median progression-free survival improvement"
      },
      {
        "type": "OS",
        "value": "+5.1 months",
        "description": "Potential median overall survival improvement"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      }
    ],
    "quantitative": "+5.1 months OS"
  },
  "weighted_score": 96
}